ZymoGenetics Sues Bristol-Myers Squibb in Patent Dispute
ePT--the Electronic Newsletter of Pharmaceutical Technology
ZymoGenetics (Seattle, WA) has sued Bristol-Myers Squibb (New York, NY) over alleged infringement of ZymoGentics's fusion-protein technology patents.
ZymoGenetics (Seattle, WA, www.zymogenetics.com) has sued Bristol-Myers Squibb (New York, NY, www.bms.com) over alleged infringement of ZymoGentics’s fusion-protein technology patents. ZymoGenetics filed the lawsuit in the US District Court for the District of Delaware and is seeking injunctive relief and damages.
“We have a number of patents on fusion-protein technology, which we believe are being infringed by Bristol-Myers Squibb,” said Bruce L.A. Carter, PhD, president and chief executive officer of ZymoGenetics. “It is important that ZymoGenetics protect its intellectual property rights for technology that it expended significant resources in developing, and we will enforce our patents through litigation when necessary.”
Amgen (Thousand Oaks, CA, www.amgen.com) and Regeneron Pharmaceuticals (Tarrytown, NY, www.regeneron.com) previously have licensed ZymoGenetics’s fusion-protein patents.
Further details about the lawsuit were not provided. At press time, Bristol-Myers Squibb had not commented on the lawsuit.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
